Trials / Not Yet Recruiting
Not Yet RecruitingNCT07061210
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-2189 | HRS-2189 |
| DRUG | Adebrelimab | Adebrelimab |
| DRUG | BP102 | BP102 |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-10-01
- Completion
- 2027-01-01
- First posted
- 2025-07-11
- Last updated
- 2025-07-11
Source: ClinicalTrials.gov record NCT07061210. Inclusion in this directory is not an endorsement.